Search results for: vertebral fracture

2014 ACR/ARHP Annual Meeting: Bone Fracture Concerns in Children

Susan Bernstein | April 1, 2015

Recognizing, reducing risk of bone fractures in pediatric patients with rheumatic disease, taking glucocorticoid therapy

Atypical Fractures Associated with Bisphosphonates

Michele B. Kaufman, PharmD, BCGP | November 1, 2014

Plus, FX006, odanacatib and other rheumatology drug news, safety updates

New Treatments Needed to Prevent Fractures in Osteoporosis

Ellen M. Field, MD, FACR, CCD | June 1, 2014

Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

Glucocorticoids a Fracture Risk at Any Dose

Kathy Holliman | March 18, 2011

Updated recommendations advocate doing more to determine fracture risk and the need for preventive therapy

Abaloparatide vs. Alendronate for Osteoporosis

Lara C. Pullen, PhD | August 10, 2020

In a clinical trial, researchers compared the efficacy of abaloparatide with alendronate in reducing the risk of fracture among postmenopausal women with osteoporosis. The findings suggest initial treatment with abaloparatide may result in greater vertebral fracture reduction than alendronate…

Payments Cut to the Bone

Norra MacReady | February 1, 2007

CMS reduces reimbursement for DXA and vertebral fracture assessment

A Long Path Forward: Complications of COVID-19 in Patients with Rheumatic Disease

Jason Liebowitz, MD, FACR | September 24, 2024

Emerging evidence shows COVID-19 infection may have long-term consequences, such as arthritis onset and more.

A Delicate Balance: How to Avoid Overmedicalization in Rheumatology

Jason Liebowitz, MD, FACR | April 9, 2024

Rheumatologist Rachelle Buchbinder, AO, MBBS (Hons), MSc, PhD, discusses reducing overdiagnosis, overtreatment, low-value care and waste in medicine.

ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline

Ruth Jessen Hickman, MD | October 10, 2023

The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…

Updated Guideline Introduces Recommendations for Prevention & Treatment of Glucocorticoid-Induced Osteoporosis

From the College | October 10, 2022

ATLANTA—The ACR released a summary of its updated guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in September. Many patients take glucocorticoids for a variety of inflammatory conditions, and anyone who is taking glucocorticoid medications and has other risk factors for osteoporosis increases their risk of developing glucocorticoid-induced osteoporosis. New osteoporosis medications and new…